<DOC>
	<DOCNO>NCT01342016</DOCNO>
	<brief_summary>The purpose study compare efficacy safety tacrolimus capsule leflunomide tablet treatment lupus nephritis .</brief_summary>
	<brief_title>A Study Compare Efficacy Safety Tacrolimus Capsules With Leflunomide Tablets Lupus Nephritis Patients</brief_title>
	<detailed_description />
	<mesh_term>Nephritis</mesh_term>
	<mesh_term>Lupus Nephritis</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Leflunomide</mesh_term>
	<criteria>body weight 40100kg diagnosed systemic lupus erythematosus , ( accord American College Rheumatology Diagnostic Criteria,1997 ) diagnose type III/ IV lupus nephritis renal biopsy within 6 month 24hr proteinuria ≥2g and/or active urinary sediment receive immunosuppressant receive routine treatment tacrolimus leflunomide within 1 month receive nonsteroidal antiinflammatory drug ( NSAIDs ) within 1 month study history allergy tacrolimus leflunomide anticipate maintenance dialysis persist 8 week ; already dialyze 2 week recruitment plan receive kidney transplantation near future history undergo kidney transplantation serum creatinine ( Scr ) ≥3mg/dl estimate glomerular filtration rate ( eGFR ) &lt; 30ml/min diabetes mellitus patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>prograf</keyword>
	<keyword>nephritis</keyword>
	<keyword>leflunomide</keyword>
	<keyword>immunosuppressant</keyword>
</DOC>